Clinical trial · Interventional
Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer
NCT05092750CI-TRIAL-00069969withdrawnPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): 0 accrual
Summary
Brief summary (as posted)
Study to determine the feasibility of Sentinel Lymph Node (SLN) mapping using novel magnetic tracers (FerroTrace) and indocyanine green (ICG) for colorectal cancer; and to evaluate safety by assessing short term toxicity associated with colonoscopic peritumoral injection of novel magnetic nanoparticles (FerroTrace) and ICG for colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FerroTraceTM | Device | — | UNRESOLVED |
| indocyanine green (ICG) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FerroTraceTM (magnetic tracer)
- description
- a special type of fluorescent dye called indocyanine green (ICG) during surgery can help surgeons find the lymph nodes that the cancer is most likely to have spread to in colorectal cancer patients.
- interventionNames
- Device: FerroTraceTM
- Drug: indocyanine green (ICG)
Primary outcomes (1)
- measure
- To assess the feasibility how the Sentinel Lymph Node (SLN) mapping by using novel magnetic tracers (FerroTrace) and using the indocyanine green (ICG) for colorectal cancer.
- timeFrame
- through study completion, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Age 18 or older * Willing to provide informed consent * Biopsy proven colon or rectal cancer * No distant metastases Exclusion criteria: * Serious medical comorbidities or other contraindications to surgery +/- adjuvant therapy as determined by the treatment team * Previous pelvic radiotherapy or radiotherapy planned prior to surgery * Allergy or intolerance to iron oxide compounds * Iron overload disorder * Allergy or intolerance to iodides * Pregnant or lactating women\*
References
Publications (0)
Data not yet available
No reference posted for this study.